136 related articles for article (PubMed ID: 12018951)
21. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
22. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2006 Jun; 396(3):537-45. PubMed ID: 16492138
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein mediates the collateral sensitivity of multidrug resistant cells to steroid hormones.
Laberge RM; Ambadipudi R; Georges E
Biochem Biophys Res Commun; 2014 May; 447(4):574-9. PubMed ID: 24747077
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
25. Differential interactions of cytochalasins with P-glycoprotein.
Zilfou JT; Smith CD
Oncol Res; 1995; 7(9):435-43. PubMed ID: 8835287
[TBL] [Abstract][Full Text] [Related]
26. Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate.
Wang C; Zhang JX; Shen XL; Wan CK; Tse AK; Fong WF
Biochem Pharmacol; 2004 Sep; 68(5):843-55. PubMed ID: 15294447
[TBL] [Abstract][Full Text] [Related]
27. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates.
Loo TW; Clarke DM
Biochemistry; 1999 Apr; 38(16):5124-9. PubMed ID: 10213617
[TBL] [Abstract][Full Text] [Related]
28. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy.
Delannoy S; Urbatsch IL; Tombline G; Senior AE; Vogel PD
Biochemistry; 2005 Oct; 44(42):14010-9. PubMed ID: 16229490
[TBL] [Abstract][Full Text] [Related]
29. A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles.
Bebawy M; Morris MB; Roufogalis BD
Anal Biochem; 1999 Mar; 268(2):270-7. PubMed ID: 10075817
[TBL] [Abstract][Full Text] [Related]
30. Reversible labeling of a chemosensitizer binding domain of p-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor.
Boer R; Dichtl M; Borchers C; Ulrich WR; Marecek JF; Prestwich GD; Glossmann H; Striessnig J
Biochemistry; 1996 Feb; 35(5):1387-96. PubMed ID: 8634268
[TBL] [Abstract][Full Text] [Related]
31. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
Shen X; Chen G; Zhu G; Fong WF
Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
[TBL] [Abstract][Full Text] [Related]
32. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport.
Eckford PD; Sharom FJ
Biochemistry; 2008 Dec; 47(51):13686-98. PubMed ID: 19049391
[TBL] [Abstract][Full Text] [Related]
33. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis.
Barakat S; Gayet L; Dayan G; Labialle S; Lazar A; Oleinikov V; Coleman AW; Baggetto LG
Biochem J; 2005 Jun; 388(Pt 2):563-71. PubMed ID: 15693753
[TBL] [Abstract][Full Text] [Related]
34. Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein.
Kokubu N; Cohen D; Watanabe T
Biochem Biophys Res Commun; 1997 Jan; 230(2):398-401. PubMed ID: 9016791
[TBL] [Abstract][Full Text] [Related]
35. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs.
Orlowski S; Garrigos M
Anticancer Res; 1999; 19(4B):3109-23. PubMed ID: 10652600
[TBL] [Abstract][Full Text] [Related]
36. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
37. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
38. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment.
Rothnie A; Storm J; McMahon R; Taylor A; Kerr ID; Callaghan R
FEBS Lett; 2005 Jul; 579(18):3984-90. PubMed ID: 16004994
[TBL] [Abstract][Full Text] [Related]
39. CJX1, an amlodipine derivative, interacts with ATPase of human P-glycoprotein.
Ji BS; He L
Cell Biol Int; 2009 Oct; 33(10):1073-8. PubMed ID: 19589390
[TBL] [Abstract][Full Text] [Related]
40. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux.
Tainton KM; Smyth MJ; Jackson JT; Tanner JE; Cerruti L; Jane SM; Darcy PK; Johnstone RW
Cell Death Differ; 2004 Sep; 11(9):1028-37. PubMed ID: 15131592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
